(Q44444407)

3 December 2017

Famotidine for infant gastro-oesophageal reflux: a multi-centre, randomized, placebo-controlled, withdrawal trial (English)

1 reference

3 December 2017

Famotidine for infant gastro‐oesophageal reflux: a multi‐centre, randomized, placebo‐controlled, withdrawal trial (English)

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01559.X

3 January 2024

1 reference

1 reference

S. R. Orenstein

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752346

3 January 2024

T. M. Shalaby

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752346

3 January 2024

S. N. Devandry

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752346

3 January 2024

C. A. Liacouras

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752346

3 January 2024

S. J. Czinn

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752346

3 January 2024

J. E. Dice

6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752346

3 January 2024

T. J. Simon

7

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752346

3 January 2024

S. P. Ahrens

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752346

3 January 2024

L. A. Stauffer

9

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?resulttype=core&format=json&query=SRC%3AMED%20AND%20EXT_ID%3A12752346

3 January 2024

language of work or name

English

0 references

publication date

1 May 2003

1 reference

full work available at URL

3 December 2017

https://api.wiley.com/onlinelibrary/tdm/v1/articles/10.1046%2Fj.1365-2036.2003.01559.x

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01559.X

https://onlinelibrary.wiley.com/doi/pdf/10.1046/j.1365-2036.2003.01559.x

3 January 2024

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01559.X

Alimentary Pharmacology & Therapeutics

3 January 2024

published in

1 reference

3 December 2017

17

1 reference

3 December 2017

9

1 reference

3 December 2017

1097-1107

1 reference

A systematic review of nonpharmacological and nonsurgical therapies for gastroesophageal reflux in infants

3 December 2017

1 reference

https://api.crossref.org/works/10.1046%2FJ.1365-2036.2003.01559.X

Efficacy of telephone teaching of conservative therapy for infants with symptomatic gastroesophageal reflux referred by pediatricians to pediatric gastroenterologists

21 January 2018

2

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01559.X

Do H2 receptor antagonists have a therapeutic role in childhood?

3 January 2024

4

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01559.X

Efficacy of cimetidine for gastric acid suppression in pediatric patients

3 January 2024

5

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01559.X

Treatment of severe reflux esophagitis with cimetidine and metoclopramide

3 January 2024

7

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01559.X

Omeprazole in infants with cimetidine-resistant peptic esophagitis.

3 January 2024

9

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01559.X

Famotidine relieves symptoms of gastroesophageal reflux disease and heals erosions and ulcerations. Results of a multicenter, placebo-controlled, dose-ranging study. USA Merck Gastroesophageal Reflux Disease Study Group

3 January 2024

10

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01559.X

Effect of famotidine on oesophageal sensitivity in gastro-oesophageal reflux disease

3 January 2024

11

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01559.X

Clinical Pharmacokinetics of Famotidine

3 January 2024

12

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01559.X

Single-dose pharmacokinetics and bioavailability of famotidine in man. Results of multicenter collaborative studies

3 January 2024

13

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01559.X

Pharmacokinetics and pharmacodynamics of famotidine in children

3 January 2024

14

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01559.X

Suppression of gastric acid secretion by intravenous administration of famotidine in children

3 January 2024

15

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01559.X

Famotidine. Pharmacokinetic properties and suppression of acid secretion in paediatric patients following cardiac surgery

3 January 2024

16

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01559.X

Pharmacokinetics and pharmacodynamics of famotidine in children with gastroduodenal ulcers.

3 January 2024

17

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01559.X

Reflux symptoms in 100 normal infants: diagnostic validity of the infant gastroesophageal reflux questionnaire

3 January 2024

20

1 reference

https://api.crossref.org/works/10.1046/J.1365-2036.2003.01559.X

3 January 2024

Identifiers

1 reference

3 December 2017

1 reference